OCUL Ocular Therapeutix Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 26 November 2019 Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

2. 19 November 2019 Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

   Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

3. 14 November 2019 Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

4. 12 November 2019 Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

   Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quarter of 2020 Topline

5. 08 November 2019 Ocular Therapeutix Announces Strategic Update and Operational Restructuring

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational

6. 05 November 2019 Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

7. 05 November 2019 Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

   Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

8. 01 October 2019 Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

   Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

9. 26 September 2019 Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

   Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

10. 29 August 2019 Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that